目的 分析恶性肿瘤患者凝血指标浓度变化的特点。方法 115例肿瘤患者分为胃癌、肠癌和肺癌组，选择健康体检者50例为对照组。分别检测患者治疗前凝血指标的水平、化疗后随时间变化凝血指标的变化和对照组凝血指标进行对比。结果 肿瘤患者血浆凝血酶原时间(prothrombin time， PT)为(12.39±1.23)s，活化部分凝血活酶时间(activated partial thromboplastin time， APTT)为(30.58±7.43)s，纤维蛋白原(fibrinogen ，FIB)为(4.71±1.72)g/L，D-二聚体(D-Dimer)为(1.32±0.16)μg/ml水平明显高于对照组，差异有统计学意义(P<0.05);不同类型肿瘤患者血浆PT、APTT、FIB、D-Dimer水平均明显高于对照组，差异有统计学意义(P<0.05)。肺癌组血浆FIB水平明显高于肠癌组、胃癌组，差异有统计学意义(P<0.05)，而肠癌组血浆FIB水平与胃癌组比较无统计学意义。胃癌组、肺癌组和肠癌组血浆FIB水平在化疗不同时期均未见明显变化。结论 凝血指标对肿瘤的早期诊断、疗效监测有一定帮助，是肿瘤患者排除、预防静脉血栓的良好指标。
Abstract
Objective To study the characteristics of blood coagulation index concentration change in tumor patients. Methods 115 cancer pationts were divided into groups of stomach cancer, colon cance and lung cancer. For the patients, the levels of blood clotting index before and after chemotherapy coagulation index changes over time were detected and blood coagulation indexes were detected in 50 cases of control group. Results In patients with cancer, plasma prothrombin time (PT) (12.39±1.23)s, activated partial thromboplastin time (APTT) (30.58±7.43)s, fibrinogen (FIB) (4.71±1.72)g/L, D- dimer (D-Dimer) (1.32±0.16 )μg/ml levels were significantly higher than in the control group (P<0.05). In patients with different types of tumor plasma PT, APTT, FIB, D-Dimer levels were significantly higher than in the control group (P<0.05). In lung cancer group, plasma FIB level was significantly higher than in colorectal cancer group and gastric cancer group (P<0.05). The plasma FIB level in gastric cancer group and colorectal cancer group was not significantly different. In gastric cancer group, lung cancer group and colorectal cancer group, plasma FIB levels did not obviously change in different periods of chemotherapy. Conclusions Coagulation indices for tumor diagnosis and curative effect monitoring have some help and are good indicators to excluded tumor, and preven venous thrombosis.
关键词
肿瘤 /
化疗 /
凝血指标
Key words
cancer /
chemotherapy /
coagulation indicators
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Ahlbrecht J, Dickmann B, et al. Tumer grade is associated with venous thrombeoembolism in patients with cancer:result from the Vienna cancerand Thrombosis study[J] .J Clin Oncol,2012,30(31):3870-3875.
[2] Tormoen G M, Haley K M, Levine R L, et al. Do circulating tumor cells play a role in coagulation and thrombosis[J]. Front Oncol, 2012, 10 (2):115.
[3] Demer M,Krause D S,schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis[J].Proc Natl Acad Sci USA,2012,109(32):13076-13081.
[4] Khorana A A, Francis C W, Culakova E, et al. Frequency, risk factor, and trends for venous thromboembolism among hospitalized cancer patients[J].Cancer,2007,110(10):2339-2346.
[5] Menapace L A,Khorana A A. The role of thromboprophylaxis in cancer patients:emerging data[J]. Curr Opin Hematol, 2010,17(5):450-456.
[6] Donati M B, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy[J].Acta Haematol, 2001,106(1-2):18-24.
[7] Haddad T C,Greeno E W. Chemotheraapy-induced thrombosis[J].Thromb Res,2006,118(5):555-568.
[8] Khorana A A. Venous thromboembolism and prognosis in cancer[J].Thromb Res,2010,125(6):490-493.
[9] 郁舒靓,韩俊庆,韩明勇,等.恶性肿瘤患者凝血指标的临床分析[J].中华临床医师杂志,2012,6(8):2048-2051.
[10] 柳庆华,许方程,宝彩芹,等.结直肠癌患者血清D-dimer与C-反应蛋白的检测及其临床意义[J].武警医学,2014,25(11):1089-1091.
[11] Kono T, Ohtsuki N, et al.Clinical characteristics of ischemic stroke in eldely patient with cancer[J].Nihon Ronen Igakkai Zasshi,2011,48(1):57-62.
[12] Mochizuki S, Yoshino T, Kojima T, et al.Therapeutic significance of a D-dimer cut-off level of>3цg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab[J]. Jpn J Clin Oncol,2010,40(10):933-937.
[13] 林 粤,韩玲霞.恶性肿瘤患者凝血指标测定的临床评价[J].现代中西医结合杂志,2006,15(5):636-637.
[14] 江吕泉,高坤祥,郑 建,等.血浆D-二聚体及纤维蛋白原在非小细胞肺癌患者围手术期监测中的应用价值[J]. 武警医学,2013,24(5):414-416.
PDF(526 KB)
